Cibus Global LLC Asset Resilience Ratio
Cibus Global LLC asset resilience ratio. Cibus Global LLC (CBUS) has an Asset Resilience Ratio of 5.81% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Cibus Global LLC fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cibus Global LLC (2016–2021)
Asset resilience ratio of Cibus Global LLC from 2016 to 2021. This chart shows how Cibus Global LLC's Asset Resilience Ratio has changed over time. Read Cibus Global LLC (CBUS) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cibus Global LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cibus Global LLC total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.04 Million | 5.81% |
| Total Liquid Assets | $3.04 Million | 5.81% |
Asset Resilience Insights
- Limited Liquidity: Cibus Global LLC maintains only 5.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cibus Global LLC Industry Peers by Asset Resilience Ratio
Compare Cibus Global LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Cibus Global LLC Asset Resilience Ratio by Year (2016–2021)
Cibus Global LLC asset resilience ratio by year from 2016 to 2021. The table below shows the annual Asset Resilience Ratio data for Cibus Global LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $0.00 | $37.19 Million | -- |
| 2020-12-31 | 18.47% | $11.70 Million | $63.33 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $88.10 Million | -- |
| 2017-12-31 | 0.56% | $402.00K | $72.17 Million | -2.66pp |
| 2016-12-31 | 3.22% | $535.00K | $16.62 Million | -- |
About Cibus Global LLC
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-th… Read more